Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 2,500 Shares of Company Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the sale, the director owned 37,406 shares in the company, valued at approximately $9,463,718. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Glaukos Stock Performance

NYSE GKOS opened at $220.03 on Friday. The firm’s 50-day moving average is $177.40 and its two-hundred day moving average is $143.58. Glaukos Corporation has a 12 month low of $80.90 and a 12 month high of $255.18. The company has a quick ratio of 4.09, a current ratio of 4.57 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The company had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same quarter last year, the firm posted ($0.16) earnings per share. Glaukos’s revenue was up 58.0% compared to the same quarter last year. As a group, research analysts anticipate that Glaukos Corporation will post 0.50 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Glaukos

Several institutional investors have recently modified their holdings of GKOS. BlackRock Inc. purchased a new stake in Glaukos during the second quarter worth approximately $1,333,318,000. Jupiter Topco LLC acquired a new position in Glaukos in the second quarter valued at approximately $679,614,000. Janus Henderson Group PLC increased its stake in Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Primecap Management Co. CA purchased a new position in Glaukos in the second quarter valued at approximately $424,969,000. Finally, William Blair Investment Management LLC purchased a new position in Glaukos in the second quarter valued at approximately $92,476,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analysts Set New Price Targets

GKOS has been the topic of a number of research reports. Zacks Research upgraded Glaukos from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 28th. Needham & Company LLC lifted their price objective on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. HC Wainwright lifted their price objective on Glaukos from $195.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Jefferies Financial Group boosted their price objective on Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. Finally, Piper Sandler reissued an “overweight” rating and set a $240.00 target price (up from $195.00) on shares of Glaukos in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.71.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.